Trifluoperazine

Trifluoperazine

SCHEMBL1590788

CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1.O=C(O)/C=C\C(=O)O

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2DRD3DRD4HTR2AHTR2C

The experimentally established mechanism targets of Trifluoperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 2/20 0.83
HTR2A known ✓ P28223 2/20 0.83
HTR2C known ✓ P28335 2/20 0.83
DRD3 known ✓ P35462 2/20 0.83
DRD4 known ✓ P21917 1/20 0.72
RAD52 P43351 3/20 0.84
FPR2 P25090 12/20 0.83
LMNA P02545 7/20 0.83
MAPT P10636 7/20 0.83
SMN1; SMN2 Q16637 6/20 0.83
MAPK1 P28482 5/20 0.83
CYP3A4 P08684 4/20 0.83
TP53 P04637 3/20 0.83
ALDH1A1 P00352 2/20 0.83
CYP1A2 P05177 2/20 0.83
ABCB1 P08183 2/20 0.83
HTR1A P08908 2/20 0.83
ADRA2A P08913 2/20 0.83
ADORA3 P0DMS8 2/20 0.83
CYP2D6 P10635 2/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoperazine SCHEMBL1590789 1.00 RAD52 (0.84) RAD52FPR2LMNAMAPTSMN1; SMN2
Trifluoperazine SCHEMBL27892292 0.93 RAD52 (0.89) RAD52FPR2LMNAMAPTSMN1; SMN2
Fluphenazine SCHEMBL565707 0.93 LMNA (0.85) RAD52FPR2LMNAMAPTSMN1; SMN2
Fluphenazine SCHEMBL565708 0.93 LMNA (0.85) RAD52FPR2LMNAMAPTSMN1; SMN2
Trifluoperazine SCHEMBL24866 0.91 FPR2 (1.00) RAD52FPR2LMNAMAPTSMN1; SMN2
Trifluoperazine SCHEMBL29603012 0.91 FPR2 (1.00) RAD52FPR2LMNAMAPTSMN1; SMN2
Trifluoperazine SCHEMBL1897003 0.91 FPR2 (1.00) RAD52FPR2LMNAMAPTSMN1; SMN2
Acetophenazine SCHEMBL2448563 0.90 LMNA (0.71) RAD52FPR2LMNAMAPTSMN1; SMN2
Trifluoperazine SCHEMBL23039392 0.90 LMNA (1.00) RAD52FPR2LMNAMAPTSMN1; SMN2
Trifluoperazine SCHEMBL29579627 0.90 LMNA (1.00) RAD52FPR2LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
US-20240016745-A1 TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME TOWA PHARMACEUTICAL CO., LTD. (JP) 2024-01-18 US disclosed
EP-4260847-A1 TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME TOWA PHARMACEUTICAL CO., LTD. (JP) 2023-10-18 EP disclosed
EP-2465539-B1 DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET FUJI CHEM IND CO LTD (JP) 2018-07-11 EP disclosed
US-9579312-B2 Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical SYSTEM C (JP) 2017-02-28 US disclosed
EP-2465540-B1 DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET FUJI CHEM IND CO LTD (JP) 2016-10-05 EP disclosed
US-9446055-B2 Disintegrating particle composition and orally rapidly disintegrating tablet FUJI CHEMICAL INDUSTRY CO., LTD. (JP) 2016-09-20 US disclosed
US-20150320735-A1 METHOD FOR TREATING/PREVENTING DISEASE USING COGNITIVE ABILITY OF CEREBRUM AND PHARMACEUTICAL SYSTEM C (JP) 2015-11-12 US disclosed
US-8900602-B2 Disintegrating particle composition and orally rapidly disintegrating tablet FUJI CHEMICAL INDUSTRY CO., LTD. (JP) 2014-12-02 US disclosed
EP-2700401-A1 METHOD FOR PRODUCING ADHESIVE PATCH, AND ADHESIVE PATCH Hisamitsu Pharmaceutical Co., Inc. (JP) 2014-02-26 EP disclosed
CN-103338789-A Pharmaceutical composition containing poorly water-soluble drug KOWA CO 2013-10-02 CN disclosed
US-20120165413-A1 DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET FUJI CHEMICAL INDUSTRY CO., LTD. (JP) 2012-06-28 US disclosed
US-20120156261-A1 DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET FUJI CHEMICAL INDUSTRY CO., LTD. (JP) 2012-06-21 US disclosed
EP-2465539-A1 DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET FUJI CHEMICAL INDUSTRY CO., LTD. (JP) 2012-06-20 EP disclosed
EP-2465540-A1 DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET FUJI CHEMICAL INDUSTRY CO., LTD. (JP) 2012-06-20 EP disclosed
US-20110092548-A1 METHOD FOR TREATING/PREVENTING DISEASE USING COGNITIVE ABILITY OF CEREBRUM AND PHARMACEUTICAL MINOWADA TAKURO 2011-04-21 US disclosed
EP-2005956-A1 METHOD FOR TREATING/PREVENTING DISEASE USING COGNITIVE ABILITY OF CEREBRUM AND PHARMACEUTICAL Minowada, Takuro (JP) 2008-12-24 EP disclosed
EP-0665009-B1 CRYSTALLINE CONDITION DISLOCATING METHOD NIPPON SHINYAKU CO LTD (JP) 2000-02-16 EP disclosed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US disclosed
EP-0665009-A1 CRYSTALLINE CONDITION DISLOCATING METHOD NIPPON SHINYAKU COMPANY, LIMITED (JP) 1995-08-02 EP disclosed